{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:28:54Z","timestamp":1793320134564,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1467-y","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T13:02:33Z","timestamp":1564059753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Systemic sclerosis medications and risk of scleroderma renal crisis"],"prefix":"10.1186","volume":"20","author":[{"given":"S. M.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Stitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. T.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Edison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. W.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"1467_CR1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989\u20132003.","journal-title":"N Engl J Med"},{"key":"1467_CR2","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3899\/jrheum.131210","volume":"41","author":"L Mouthon","year":"2014","unstructured":"Mouthon L, Bussone G, Berezne A, Noel LH, Guillevin L. Scleroderma Renal Crisis. J Rheumatol. 2014;41:1040\u20138.","journal-title":"J Rheumatol"},{"key":"1467_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/BOR.0b013e3283588dcf","volume":"24","author":"VK Shanmugam","year":"2012","unstructured":"Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 2012;24:669\u201376.","journal-title":"Curr Opin Rheumatol"},{"key":"1467_CR4","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/j.lpm.2014.02.031","volume":"43","author":"VD Steen","year":"2014","unstructured":"Steen VD. Kidney involvement in systemic sclerosis. Presse Med. 2014;43:e305\u201314.","journal-title":"Presse Med"},{"issue":"1","key":"1467_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3899\/jrheum.171186","volume":"46","author":"Sarah M. Gordon","year":"2018","unstructured":"Gordon SM, Stitt RS, Nee R, Bailey WT, Little DJ, Knight KR, et al. Risk Factors for Future Scleroderma Renal Crisis at Systemic Sclerosis Diagnosis. J Rheumatol. 2019;46(1):85\u201392.","journal-title":"The Journal of Rheumatology"},{"key":"1467_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","volume":"113","author":"VD Steen","year":"1990","unstructured":"Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme(ACE) inhibitors. Ann Intern Med. 1990;113:352\u20137.","journal-title":"Ann Intern Med"},{"key":"1467_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0025-6196(12)60418-2","volume":"60","author":"VL Beckett","year":"1985","unstructured":"Beckett VL, Donadio JV Jr, Brennan LA Jr, Conn DL, Osmundson PJ, Chao EY, et al. Use of captopril as early therapy for renal scleroderma: a prospective study. Clin Proc. 1985;60:763.","journal-title":"Clin Proc"},{"key":"1467_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","volume":"133","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000;133:600\u20133.","journal-title":"Ann Intern Med"},{"key":"1467_CR9","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","volume":"41","author":"VD Steen","year":"1998","unstructured":"Steen VD, Medsger TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41:1613.","journal-title":"Arthritis Rheum"},{"key":"1467_CR10","doi-asserted-by":"publisher","first-page":"29830","DOI":"10.1002\/art.10589","volume":"46","author":"PJ Demarco","year":"2002","unstructured":"Demarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al. Predictors and outcomes of scleroderma renal crisis. Arthritis Rheum. 2002;46:29830\u20132989.","journal-title":"Arthritis Rheum"},{"key":"1467_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1046\/j.1445-5994.2003.00358.x","volume":"33","author":"JG Walker","year":"2003","unstructured":"Walker JG, Ahern MJ, Smith MD, Coleman M, Pile K, Rischmueller M, et al. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J. 2003;33:216\u201320.","journal-title":"Intern Med J"},{"key":"1467_CR12","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3899\/jrheum.080806","volume":"36","author":"V Codullo","year":"2009","unstructured":"Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, Papa ND, Franceschini F, Guiducci S, Morozzi G, Ruffatti A, Ferri C, Giacomelli R, Matucci-Cerninic M, Valentini G, Montecucco C. Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol. 2009;36:1464\u20139.","journal-title":"J Rheumatol"},{"key":"1467_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","volume":"100","author":"H Penn","year":"2007","unstructured":"Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis:patient characteristics and long-term outcomes. Q J Med. 2007;100:485\u201394.","journal-title":"Q J Med"},{"key":"1467_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/ard.2006.066985","volume":"67","author":"L Teixeira","year":"2008","unstructured":"Teixeira L, Mouthon L, Mahr A, Berezne A, Agard C, Mehrenberger M, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis. 2008;67:110\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1467_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","volume":"51","author":"L Guillevin","year":"2012","unstructured":"Guillevin L, Berezne A, Seror R, Teixeira L, Pourrat J, Mahr A, Hachulla E, Agard C, Cabane J, Vanhille P, Harle JR, Deleveauz I, Mouthon L. Scleroderma renal crisis: a retrospective multicenter study on 91 patients and 427 controls. Rheumatology. 2012;51:460\u20137.","journal-title":"Rheumatology"},{"key":"1467_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","volume":"43","author":"M Hudson","year":"2014","unstructured":"Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014;43:666.","journal-title":"Semin Arthritis Rheum"},{"key":"1467_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","volume":"42","author":"KM Walker","year":"2012","unstructured":"Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails- a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42:42\u201355.","journal-title":"Semin Arthritis Rheum"},{"key":"1467_CR18","first-page":"S135","volume":"31","author":"G Montanelli","year":"2013","unstructured":"Montanelli G, Beretta L, Santaniello A, Scorza R. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in and Italian case series. Clin Exp Rheumatol. 2013;31:S135\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"1467_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.humpath.2010.05.018","volume":"42","author":"L Mouthon","year":"2011","unstructured":"Mouthon L, Mehrenberger M, Teixeira L, Fakhouri F, Berezne A, Guillevin L, et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol. 2011;42:95\u2013102.","journal-title":"Hum Pathol"},{"key":"1467_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/qjmed\/hct111","volume":"106","author":"H Penn","year":"2013","unstructured":"Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJ Med. 2013;106:839\u201348.","journal-title":"QJ Med"},{"key":"1467_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.ajkd.2009.02.015","volume":"54","author":"N Dhaun","year":"2009","unstructured":"Dhaun N, MacIntyre IM, Bellamy COC, Kluth DC. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis. 2009;54:726\u201331.","journal-title":"Am J Kidney Dis"},{"key":"1467_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1053\/j.ajkd.2013.04.016","volume":"62","author":"H Izzedine","year":"2013","unstructured":"Izzedine H, Rouvier P, Deray G. Endothelin receptor antagonism-based treatment for scleroderma renal crisis. Am J Kidney Dis. 2013;62:394\u2013400.","journal-title":"Am J Kidney Dis"},{"key":"1467_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3899\/jrheum.111229","volume":"39","author":"FA Mendoza","year":"2012","unstructured":"Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012;39:1241\u20137.","journal-title":"J Rheumatol"},{"key":"1467_CR24","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655.","journal-title":"N Engl J Med"},{"key":"1467_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708.","journal-title":"Lancet Respir Med"},{"key":"1467_CR26","unstructured":"Military Health System and the Defense Health Agency. Military Health System Review Final Report 2014. \n                              https:\/\/health.mil\/About-MHS\n                              \n                           . Accessed 22 July 2019."},{"key":"1467_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.7205\/MILMED-D-12-00168","volume":"178","author":"KA Dorrance","year":"2013","unstructured":"Dorrance KA, Ramchandani S, Neil N, Fisher H. Leveraging the military health system as a laboratory for health care reform. Mil Med. 2013;178:142\u20135.","journal-title":"Mil Med"},{"key":"1467_CR28","first-page":"1","volume":"2010","author":"VK Shanmugam","year":"2010","unstructured":"Shanmugam VK, Steen VD. Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy. Int J Rheumatol. 2010;2010:1\u20138.","journal-title":"Int J Rheumatol"},{"key":"1467_CR29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1681\/ASN.2010091001","volume":"22","author":"RE Schmieder","year":"2011","unstructured":"Schmieder RE, Mann JFE, Schumacher H, Gao P, Mancia G, Weber MA, McQueen M, Koon T, Yusuf S. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol. 2011;22:1353\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"1467_CR30","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1681\/ASN.2006050517","volume":"17","author":"D de Zeew","year":"2006","unstructured":"de Zeew D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006;17:2100\u2013210.","journal-title":"J Am Soc Nephrol"},{"key":"1467_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/01.CIR.0000133312.96477.48","volume":"110","author":"K Klausen","year":"2004","unstructured":"Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32\u20135.","journal-title":"Circulation"},{"key":"1467_CR32","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","volume":"106","author":"HL Hillege","year":"2002","unstructured":"Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777\u201382.","journal-title":"Circulation"},{"key":"1467_CR33","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/ard.61.8.682","volume":"61","author":"R Livi","year":"2002","unstructured":"Livi R, Teghini L, Pignone A, Generini S, Matucci-Cerinic M, Cagnoni M. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis. 2002;61:682\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1467_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5414\/CNP70110","volume":"70","author":"B Seilberlich","year":"2008","unstructured":"Seilberlich B, Hunzelmann N, Krieg T, Weber M, Shulze-Lohoff E. Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity. Clin Nephrol. 2008;70:110\u20137.","journal-title":"Clin Nephrol"},{"key":"1467_CR35","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/art.1780390622","volume":"39","author":"R Rivolta","year":"1996","unstructured":"Rivolta R, Mascagni B, Berruti V, di Palo FQ, Elli A, Scorza R, et al. Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy. Arthritis Rheum. 1996;39:1030\u20134.","journal-title":"Arthritis Rheum"},{"key":"1467_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1365-2125.2001.01325.x","volume":"51","author":"PT Daley-Yates","year":"2001","unstructured":"Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. Br J Clin Pharmacol. 2001;51:103\u20135.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1467-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T23:12:34Z","timestamp":1595545954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1467-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1467-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"4 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study (#418335) was approved by the Walter Reed National Military Medical Center Institutional Review Board (IRB) with a full waiver of consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}